Results 1 to 10 of about 4,940 (173)

Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross-Sectional Study. [PDF]

Pediatr Pulmonol
ABSTRACT Introduction New RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers.
Rose A, Datta RR, Di Chiara C, Piché-Renaud PP, Morris SK.   +4 more
europepmc   +2 more sources

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children

Human Vaccines and Immunotherapeutics, 2021
To date, there is no consensus regarding palivizumab prophylaxis for respiratory syncytial virus infection. The purpose of this study is to assess the effectiveness of palivizumab prophylaxis to prevent respiratory syncytial virus-related infection ...
Natividad Viguria, Ana Navascues, Regina Juanbeltz   +2 more
exaly   +2 more sources

Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives. [PDF]

Pediatr Allergy Immunol
Evolution of RSV immunoprophylaxis: from the palivizumab era to next‐generation monoclonal antibodies and future perspectives. Created in BioRender. Abstract The burden of respiratory syncytial virus (RSV) remains a major global health concern in early childhood, responsible for substantial morbidity, hospitalizations, and deaths, particularly in ...
Bizot E, Portet Sulla V, Vauloup-Fellous C, Rameix-Welti MA, Gajdos V, Seddiki N.   +5 more
europepmc   +2 more sources

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months [PDF]

Children
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) in infants and young children, with significant morbidity, hospitalizations, and healthcare costs.
Andreea Văduva, Alexandru Dinulescu, Anca Cristina Drăgănescu, Sorin Claudiu Man, Doina Anca Pleșca   +4 more
doaj   +2 more sources

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease

Drug, Healthcare and Patient Safety, 2023
Shaun O’Hagan,1,2 Niamh Galway,3 Michael D Shields,3,4 Peter Mallett,1,4 Helen E Groves1,2 1Paediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland; 2Wellcome-Wolfson Institute for Experimental Medicine, Queen ...
Michael D Shields, Helen E Groves
exaly   +2 more sources

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen. [PDF]

PLoS ONE, 2017
Monthly injections of palivizumab during the respiratory syncytial virus (RSV) season in at-risk infants reduces RSV-associated hospitalizations. However, the additive effect of naturally acquired immunity remains unclear. The objective of this study was
Jennifer Claydon, Amitava Sur, Allison Callejas, Mihoko Ladd, Eddie Kwan, Richard Taylor, Stuart E Turvey, Alfonso Solimano, Pascal M Lavoie, Nico Marr   +9 more
doaj   +1 more source

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. [PDF]

PLoS ONE, 2015
To evaluate the safety and tolerability of palivizumab for RSV prophylaxis in high-risk children in everyday practice.High-risk children prophylaxed against RSV infection were recruited into a prospective, observational, Canadian RSV Evaluation Study of ...
Jinghan Jenny Chen, Parco Chan, Bosco Paes, Ian Mitchell, Abby Li, Krista L Lanctôt, CARESS investigators   +6 more
doaj   +1 more source

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection

Viruses, 2023
(1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been ...
Hasindu S. Edirisinghe, Anushi E. Rajapaksa, Simon G. Royce, Magdy Sourial, Robert J. Bischof, Jeremy Anderson, Gulcan Sarila, Cattram D. Nguyen, Kim Mulholland, Lien Anh Ha Do, Paul V. Licciardi   +10 more
doaj   +1 more source

Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection

BMC Pediatrics, 2021
Background The prophylactic use of anti-respiratory syncytial virus (RSV) antibody (palivizumab) for severe RSV infection is not approved in Japan in specified groups of infants with neuromuscular diseases or other rare diseases associated with reduced ...
Masaaki Mori, Shinichi Watabe, Tomoaki Taguchi, Hisaya Hasegawa, Mika Ishige, Naoyuki Tanuma, Akihiro Hirakawa, Ryuji Koike, Satoshi Kusuda   +8 more
doaj   +1 more source

Quantitative Analysis of Antibody Survival across the Infant Digestive Tract Using Mass Spectrometry with Parallel Reaction Monitoring

Foods, 2020
Orally delivered antibodies may be useful for the prevention of enteric pathogen infection, but to be effective they need to survive intact across digestion through the gastrointestinal tract.
Bum Jin Kim, Jiraporn Lueangsakulthai, Baidya Nath P. Sah, Brian Scottoline, David C. Dallas   +4 more
doaj   +1 more source